Sigrid Hatse1, Marta Serena1, Christof Vulsteke2, Kevin Punie3, Patrick Neven4, Ann Smeets4, Annouschka Laenen5, Hans Wildiers6. 1. Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium. 2. Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. 3. Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. 4. Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. 5. Interuniversity Centre for Biostatistics and Statistical Bioinformatics, Leuven, Belgium. 6. Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be.
Abstract
PURPOSE: The aim of this study is to assess baseline mean leukocyte telomere length (TL) as a potential predictive factor for chemotherapy toxicity and a prognostic marker for long-term outcome in early breast cancer (BC) patients. METHODS: 445 BC patients were selected, diagnosed between 2007 and 2010 with early BC and treated with (neo)adjuvant fluorouracil, epirubicin and cyclophosphamide (FEC) or with FEC and Docetaxel (FEC-D). RT-qPCR was performed on germline DNA samples collected at diagnosis before any treatment, to measure mean leukocyte TL. Uni- and multivariable logistic regression or Cox proportional hazard regression analyses were carried out to assess correlation between baseline TL and toxicity parameters (derived from the medical chart) or longer-term outcome. RESULTS: Baseline TL correlated with age as expected (p = 0.005), but not with febrile neutropenia (n = 97), left ventricular ejection fraction >10% decrease (n = 17) nor other toxicity endpoints measured (all p > 0.05). TL was neither associated with overall survival, breast cancer specific survival or distant disease-free survival (all p > 0.05). CONCLUSIONS: Baseline TL is not associated with chemotherapy-related toxicity nor long-term outcome in BC patients.
PURPOSE: The aim of this study is to assess baseline mean leukocyte telomere length (TL) as a potential predictive factor for chemotherapy toxicity and a prognostic marker for long-term outcome in early breast cancer (BC) patients. METHODS: 445 BC patients were selected, diagnosed between 2007 and 2010 with early BC and treated with (neo)adjuvant fluorouracil, epirubicin and cyclophosphamide (FEC) or with FEC and Docetaxel (FEC-D). RT-qPCR was performed on germline DNA samples collected at diagnosis before any treatment, to measure mean leukocyte TL. Uni- and multivariable logistic regression or Cox proportional hazard regression analyses were carried out to assess correlation between baseline TL and toxicity parameters (derived from the medical chart) or longer-term outcome. RESULTS: Baseline TL correlated with age as expected (p = 0.005), but not with febrile neutropenia (n = 97), left ventricular ejection fraction >10% decrease (n = 17) nor other toxicity endpoints measured (all p > 0.05). TL was neither associated with overall survival, breast cancer specific survival or distant disease-free survival (all p > 0.05). CONCLUSIONS: Baseline TL is not associated with chemotherapy-related toxicity nor long-term outcome in BC patients.
Authors: Jing Shen; Marilie D Gammon; Mary Beth Terry; Patrick T Bradshaw; Qiao Wang; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella Journal: Breast Cancer Res Treat Date: 2012-04-12 Impact factor: 4.872
Authors: Matthias Schwenkglenks; Ruth Pettengell; Christian Jackisch; Robert Paridaens; Manuel Constenla; André Bosly; Thomas D Szucs; Robert Leonard Journal: Support Care Cancer Date: 2010-03-20 Impact factor: 3.603
Authors: Kathleen Meeske; Ashley Wilder Smith; Catherine M Alfano; Bonnie A McGregor; Anne McTiernan; Kathy B Baumgartner; Kathleen E Malone; Bryce B Reeve; Rachel Ballard-Barbash; Leslie Bernstein Journal: Qual Life Res Date: 2007-04-25 Impact factor: 4.147
Authors: K Wenn; L Tomala; S Wilop; L Vankann; C Hasenbank; O Frank; A Hochhaus; F J Giles; T Lange; M C Müller; S Koschmieder; F Beier; P Ziegler; T H Brümmendorf Journal: Leukemia Date: 2015-09-15 Impact factor: 11.528
Authors: C P Schröder; G B Wisman; S de Jong; W T van der Graaf; M H Ruiters; N H Mulder; L F de Leij; A G van der Zee; E G de Vries Journal: Br J Cancer Date: 2001-05-18 Impact factor: 7.640